HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Keeps Hands On Consumer Product Wheel In Opting Against Split

This article was originally published in The Pink Sheet

Executive Summary

Pfizer didn't cite its consumer health business in announcing it will retain current structure, but best-selling Lipitor's cholesterol treatment indication is the most coveted indication yet to be available OTC.

You may also be interested in...



Stronger Together: Pfizer Decides Against A Split

The pharma giant's decision not to break up into two separate publicly traded companies as it has been contemplating for several years reflects an improved growth outlook and the inability to unlock trapped value. Now Pfizer can finally get on with business.

Pfizer Likes Consumer Business Right Where It Is, Or Eventually Could Be

Driven by US sales of Nexium 24HR and Advil, Pfizer's fiscal 2016 first-quarter consumer product revenues increased 2% to $822m. CEO Ian Read says Pfizer is open to adding to or selling off its consumer business, but currently likes it just where it is.

Light Still On For Switches After Pfizer Pulls Plug On OTC Lipitor

A 1,200-subject actual use trial to simulate the OTC use of Lipitor 10 mg did not meet its primary objectives of demonstrating patient compliance with the direction to check low-density lipoprotein cholesterol level and after checking their LDL-C level take appropriate action based on test results.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS123117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel